What Dafne 35 Treats: Main Uses and Benefits

This medication plays a role in managing symptoms related to hormonal sensitivity in women of reproductive age. The medicine is commonly used in situations involving certain distressing symptoms that interfere with daily functioning.

---

Management of Androgen-Related Symptoms

Dafne 35 is used in situations involving symptoms related to heightened physiological activity, specifically managing moderate to severe acne and seborrhoea (excessively oily skin) when prior topical treatments or systemic antibiotic therapy were not appropriate or were unsuccessful. It is also relevant for easing symptoms related to excessive unwanted hair growth (hirsutism), often applied in clinical contexts like Polycystic Ovary Syndrome (PCOS).

“It is commonly used when symptoms of acne or hair growth have not been successfully resolved by other standard treatments.”

The combination of ingredients supports the patient by assisting with easing the overall symptom load of persistent skin blemishes and helps improve day-to-day comfort during symptomatic periods. Additionally, the hormonal component contributes to improved cycle stability and assists with providing effective contraceptive support.

Quick Fact: Relevant for Androgen-Sensitive Skin Symptoms and Menstrual Irregularities

Regulatory References

1. European Medicines Agency (EMA) review

Dafne 35 is strictly for use by women of reproductive age with specific androgen-related symptoms and must not be used solely for contraception. Eligibility is defined by formal contraindications and specific medical conditions, as mandated by regulatory authorities.

Approved Population and Primary Restrictions

• Approved Use: Women of reproductive age requiring treatment for moderate to severe acne or hirsutism where prior local or systemic antibiotic treatments have failed. Use is only permitted post-menarche.
• Usage Restriction: The medicine is explicitly contraindicated for use as a contraceptive alone. It must also not be used in combination with any other hormonal contraceptive (pill, patch, or ring).
• Treatment Duration: Use must be discontinued 3 to 4 cycles after the treated androgen-dependent condition has fully resolved.

Absolute Contraindications (Must Not Use)

The medicine is absolutely contraindicated (must not be used) in the presence of any of the following conditions:

• Thromboembolic Risk: Current or history of Venous or Arterial Thromboembolism (VTE/ATE, such as DVT, Pulmonary Embolism, Stroke, or Myocardial Infarction), or a known inherited predisposition for these conditions.
• Oncologic Conditions: Current or history of liver tumours, meningioma, or other known sex-steroid influenced malignancies (e.g., breast cancer).
• Hepatic Disease: Severe hepatic disease until liver function has returned to normal.
• Specific Comorbidities: Severe diabetes mellitus with vascular changes, migraine with focal neurological symptoms, or severe uncontrolled hypertension.
• Physiological Status: Known or suspected pregnancy and lactation/breastfeeding.

Population Limitations

• Age and Smoking: Women over 35 who smoke are advised against use due to increased cardiovascular risk.
• Geriatric Use: Use in older adults (post-menopause) is not established as it is outside the approved indication.

Interactions with other medicines and products

All interaction information for Dafne 35 (Cyproterone acetate / Ethinyl Estradiol) is based strictly on documentation from government regulatory authorities.

Formal Contraindications

Co-administration is strictly prohibited with other hormonal contraceptive products. The medicine is also formally contraindicated for co-administration with specific Hepatitis C Virus (HCV) combination therapies, including medicinal products containing Ombitasvir / Paritaprevir / Ritonavir (with or without Dasabuvir), Glecaprevir / Pibrentasvir, or Sofosbuvir / Velpatasvir / Voxilaprevir, due to the documented risk of significant liver enzyme elevation (ALT).

Exposure-Modifying Substances

Certain substances can modify the clearance of the hormones via enzyme-mediated pathways. Medications that act as enzyme inducers, such as the anticonvulsants Phenytoin and Carbamazepine, the antibiotic Rifampicin, and the herbal product St. John's Wort (Hypericum perforatum), may increase the clearance of the hormones, potentially reducing their systemic exposure. Conversely, strong CYP3A4 inhibitors, such as Ketoconazole or Clarithromycin, may decrease hormone clearance, leading to increased exposure.

Pharmacodynamic Effects

Dafne 35 can affect the blood concentration of co-administered medicines; for example, it is documented to induce the glucuronidation of Lamotrigine, resulting in a reduction in its plasma concentration.

Administration Conditions

If vomiting occurs within 3 to 4 hours after tablet intake, the absorption of the active ingredients may be incomplete, requiring specific timing procedures as outlined in the prescribing information to maintain adequate exposure.

Dafne 35 modulates the hypothalamic-pituitary-ovarian (HPO) axis through the combined action of its steroidal components. Ethinylestradiol provides a potent agonist effect on estrogen receptors ( ERalpha and ERbeta) primarily in the anterior pituitary gland and hypothalamus. This interaction initiates a negative feedback loop that suppresses the pulsatile release of gonadotropin-releasing hormone (GnRH) from the hypothalamus and, consequently, the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary. The resultant low gonadotropin levels inhibit follicular development and ovulation.

Cyproterone acetate (CPA), a progestin and anti-androgen, acts as an agonist at the progesterone receptor (PR), contributing to the central suppression of GnRH/LH/FSH. Peripherally, CPA functions as a competitive antagonist at the androgen receptor (AR), blocking the binding of endogenous androgens like testosterone and dihydrotestosterone (DHT) at target tissues such as the sebaceous glands and hair follicles. Furthermore, CPA exhibits an inhibitory effect on 5alpha-reductase, the enzyme responsible for converting testosterone to the more potent DHT. This dual peripheral mechanism reduces androgenic signaling at the cellular level, leading to system-level physiological changes in androgen-sensitive tissues.

Dafne 35 is administered exclusively by the oral route as a fixed-dose coated tablet. The standard regimen involves taking one tablet daily, containing 2 mg Cyproterone acetate and 0.035 mg Ethinyl Estradiol. This medicine is used according to a strict 28-day cyclic pattern. Each cycle consists of 21 consecutive days of active tablet intake, followed by a 7-day interval that is either tablet-free or utilizes inactive tablets.

Tablet-taking must occur at approximately the same time each day with some liquid to maintain consistency in the administration schedule. Usage begins on the first day of the menstrual cycle, and for women starting post-partum or post-abortion, specific initiation protocols apply, typically starting between Day 21 and Day 28. The duration of treatment is generally extended over several months, and the medicine is officially withdrawn three to four cycles after the clinical condition being managed has completely resolved.

Procedural guidelines address delayed intake: if the delay in taking a tablet is less than 12 hours, the tablet should be taken immediately. If the delay extends beyond 12 hours, the expected efficacy may be reduced, and the procedural instructions outline the subsequent need for additional non-hormonal barrier methods to maintain the treatment plan.

Dafne 35: Recent Clinical Evidence

This overview summarizes the clinical research structure for the Cyproterone acetate/Ethinyl Estradiol combination (Dafne 35), describing the study designs and general patterns observed, while strictly avoiding clinical advice or interpretation of results.

---

Research Evidence for Androgen-Sensitive Skin Conditions

Research included Randomized Controlled Trials (RCTs) where the medicine was studied for moderate to severe acne and excessive oily skin (seborrhoea). Studies measured standardized assessments of acne severity grade and lesion counts. Trials reported patterns observed in the research that included measured changes in severity scores and measurements of skin oiliness across observed populations. The evidence quality varies across studies, impacting the certainty of differentiating its specific effects.

Research Evidence for Hirsutism

Research explored the use of the medicine in women with hirsutism (unwanted hair growth), utilizing RCTs and Systematic Reviews. Outcomes were measured using the Ferriman-Gallwey (F-G) score to track quantitative changes over long periods, typically six to twelve months or longer. The trials reported patterns observed in the studies, including measured changes in F-G scores across the follow-up duration. A key limitation is that sample sizes were modest in some comparative trials.

Contraceptive Action and Evidence Gaps

The dual composition means its contraceptive and cycle-regulating effects have been extensively observed in long-term observational studies relevant to Combined Oral Contraceptives (COCs). Studies confirmed the consistent suppression of ovulation and the establishment of regular bleeding cycles. The evidence describes this effect as an inherent pharmacological property of the hormonal dose.

However, long-term effects are not fully established regarding the durability of measured outcomes once the medicine is stopped. The research base highlights that comparative evidence is lacking for many head-to-head trials against the newest formulations, and the recurrence of androgen-related symptoms upon discontinuation is an area where more targeted long-term observational studies are needed.

Key Studies & References Guideline No. 444: Hirsutism: Evaluation and Treatment – SOGC (2023)

Common questions about Dafne 35 (FAQ)

Q: Is Dafne 35 primarily an acne treatment or a contraceptive pill?

Official regulatory documents state that this medicine is for the treatment of moderate to severe acne and/or excessive unwanted hair growth (hirsutism). Because it also contains hormones that provide a contraceptive effect, official use is restricted: it must not be used solely for the purpose of contraception, nor taken at the same time as any other hormonal contraceptive.

---

Q: Is the contraceptive action of Dafne 35 effective if used as directed?

When taken regularly, this medicine works by suppressing the body's natural cycle of ovulation, which provides an effective contraceptive effect. Official product information indicates that adequate suppression of the reproductive system is generally attained after seven consecutive days of uninterrupted tablet intake.

---

Q: Why is Dafne 35 often associated with a higher risk of blood clots compared to some other hormonal contraceptives?

Epidemiological studies reviewed by regulatory bodies indicate an increased risk of venous thromboembolism (VTE), which refers to blood clots. These studies suggest that the VTE incidence is approximately 1.5 to 2 times higher in users of this medicine compared with users of certain other combined oral contraceptives, such as those containing levonorgestrel.

---

Q: Is Dafne 35 considered a 'first-line' treatment for acne and hirsutism?

No. According to the official regulatory documents, for the treatment of acne, this medicine should be used only after topical therapies or systemic antibiotic treatments have been unsuccessful. This requirement indicates that it is not positioned as an initial or 'first-line' treatment option.

---

Q: What kind of clinical review process led to the drug's continued approval in some regions despite safety concerns?

Following a regulatory review by European bodies, including the Pharmacovigilance Risk Assessment Committee (PRAC), it was concluded that the benefits of the medicine still outweigh the risks. This finding was conditional on implementing specific measures to minimize the officially documented risk of blood clots (VTE) for users.

---

Q: Can Dafne 35 be taken during the postpartum period?

Official guidelines outline protocols for starting the medicine between days 21 to 28 after delivery or a second-trimester abortion. However, official product information states that the medicine is contraindicated (should not be used) during breastfeeding, due to the potential for active substances to pass into breast milk.

---

Q: Can Dafne 35 be used by women with polycystic ovary syndrome (PCOS)?

The medicine is officially indicated for the management of severe acne and/or hirsutism. Regulatory bodies note that women who are diagnosed with polycystic ovary syndrome (PCOS), a condition associated with these symptoms, may be included in the user group.

---

Q: What are the specific signs of a blood clot mentioned in the Dafne 35 patient information leaflet?

Patient leaflets advise looking for warning signs such as sudden, severe pain or swelling in one leg, an unusual sudden cough, severe pain in the chest, or partial/complete loss of vision. The leaflet advises seeking medical attention immediately if any of these signs are experienced.

---

Q: Are there any documented effects of Dafne 35 on mood, such as anxiety or depression?

Officially listed adverse reactions include depressive mood, mood swings, and nervousness. Furthermore, regulatory documentation also notes a serious association with severe depression.

---

Q: How long does it typically take to see improvement in acne or excessive hair growth (hirsutism) while taking Dafne 35?

Improvement in androgen-related symptoms is not immediately achieved. Official information indicates that full therapeutic efficacy is generally gradual and may take several months. Treatment is advised to continue for at least 3 to 4 cycles after the condition has completely resolved.

---

Q: Is there a known link between Dafne 35 and an increased risk of certain cancers, like breast or cervical cancer?

The medicine is strictly contraindicated for users with a current or history of liver tumors or meningioma. Warnings regarding the potential for an increase in breast and cervical cancer risk, as applied to all Combined Oral Contraceptives, are also considered relevant to this medicine.

---

Q: What are the instructions regarding travel, especially long-haul flights, while taking Dafne 35?

Regulatory safety information highlights that long periods of immobility, such as during long-haul travel, increase the risk of blood clots (VTE). Users are advised that precautions, such as mobilizing the legs regularly, are often necessary.

---

Q: What is chloasma and is it a potential side effect of Dafne 35?

Chloasma refers to brown, blotchy spots that can appear on the skin, particularly the face. It is a documented potential side effect associated with the use of this medicine. Patients are advised in official literature to avoid exposure to the sun or ultraviolet light to help minimize this risk.

---

Q: Does Dafne 35 protect against sexually transmitted diseases (STDs)?

No. Official patient information clearly states that this medicine, like all hormonal contraceptives, provides no protection against HIV infection (AIDS) or other sexually transmitted diseases.

---

Q: What happens to the body's natural hormone production when taking Dafne 35?

The hormonal components suppress the body's natural signaling pathway, known as the hypothalamic-pituitary-ovarian axis. This suppression means that the body's natural cycle of ovulation and hormonal release is temporarily stopped while taking the active tablets.

---

Q: Are there different versions of Dafne 35 (e.g., ED/28-day vs 21-day packs)?

The standard regimen involves 21 active tablets followed by a 7-day interval. Some formulations, such as Dafne-35 ED, include an extended pack with 7 inactive (non-hormonal) tablets to help users maintain the 28-day cyclic pattern.

---

Q: Can taking Dafne 35 make contact lenses uncomfortable?

Yes, official patient information documents state that contact lens wearers may experience discomfort or a change in their lens tolerance while using this medicine.

---

Q: Is it true that patients with diabetes or high blood pressure have an increased risk when taking Dafne 35?

The medicine is strictly contraindicated in the presence of severe diabetes mellitus with vascular changes or severe uncontrolled hypertension. For all users, conditions like hypertension are recognized as risk factors that may necessitate careful clinical monitoring during use.

---

Q: Does Dafne 35 have any effect on blood sugar levels?

For women with diabetes, the official patient information mentions that a mild increase of blood sugar is a possible effect. Regular monitoring is often required for patients with a history of diabetes or related conditions.

---

Q: What kind of monitoring (e.g., blood pressure checks) is recommended when starting Dafne 35?

A thorough general medical examination is advised before starting, and periodically during use. This typically includes measurements of body weight and blood pressure, along with a gynecological examination.

---

Q: How does the concentration of hormones in Dafne 35 compare to 'low-dose' birth control pills?

The product contains 35, mu g of Ethinyl Estradiol (EE). In regulatory context, this concentration is recognized as a standard estrogen component dose for a combined oral contraceptive.

---

Q: Is Dafne 35 associated with changes to the skin like rash or hives?

Skin rash is listed as an uncommon adverse reaction in official documents. Other potential skin changes include the risk of chloasma (blotchy spots) and blister-like rash (herpes gestationis) in rare cases.

---

Q: Why was Dafne 35 temporarily banned or restricted in some countries?

Some national authorities temporarily suspended its use or restricted its indications due to the heightened, officially documented risk of Venous Thromboembolism (VTE). This action was later reconciled with a Europe-wide decision to continue use under strict risk-minimization measures.

---

Q: Does Dafne 35 affect the results of any common blood tests?

Patient leaflets advise informing medical staff that this medicine is being taken before any blood tests are performed, as it may interfere with test results.

---

Q: Is the risk of blood clots comparable between Dafne 35 and third-generation combined oral contraceptives?

Regulatory data indicates that the VTE risk is higher in users of this medicine compared to levonorgestrel-containing COCs. The documented risk is generally considered to be in the same range as that of other combined hormonal contraceptives that contain third-generation progestins.

How to Store and Dispose of Dafne 35 (Cyproterone Acetate/Ethinyl Estradiol)

Dafne 35 must be stored according to official regulatory specifications to maintain the product's stability and efficacy.

Requirement Type	Official Labeled Condition
Temperature & Environment	Store at controlled room temperature, typically below 30 C (e.g., 15 C to 30 C), away from moisture.
Protection	Keep protected from direct sunlight and excessive heat.
Child Safety	Must be kept out of sight and reach of children.

Do not use the medication past the labeled expiry date or if the original blister packaging is torn or tampered with. Proper disposal is mandatory: unused or expired Dafne 35 must not be placed in household garbage or poured down the sink or toilet. Instead, it must be disposed of according to local regulatory programs, often requiring return to a pharmacist or designated collection point.